Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.39 |
| ▸ | APP | P05067 | 3/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | GAK | O14976 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | STK10 | O94804 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.33 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217203 | 0.84 | PARP1 (0.44) | EGFRAPPFLT1GAKPARP1 | |
| SCHEMBL18630259 | 0.79 | EGFR (0.41) | EGFRAPPFLT1GAKPARP1 | |
| SCHEMBL5453911 | 0.79 | EGFR (0.46) | EGFRGAKALKRIPK2STK10 | |
| SCHEMBL145141 | 0.76 | PDE4A (0.53) | EGFRFLT1GAKPARP1 | |
| SCHEMBL19044344 | 0.76 | EGFR (0.39) | EGFRAPPFLT1GAKPARP1 | |
| SCHEMBL1766094 | 0.76 | CSF1R (0.42) | EGFRFLT1KDR | |
| SCHEMBL2082154 | 0.76 | EGFR (0.51) | EGFRKDRPI4KAPI4K2BPI4K2A | |
| SCHEMBL14579633 | 0.76 | CHEK1 (0.44) | EGFRPARP1KDR | |
| SCHEMBL13702434 | 0.76 | EGFR (0.32) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4417636 | 0.76 | NR4A2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112939948-B | Novel quinazoline-containing compound, intermediate and application thereof | 苏州美诺医药科技有限公司 | 2022-05-17 | — | — | CN | disclosed |
| WO-2021115432-A1 | NOVEL QUINAZOLINE-CONTAINING COMPOUND, AND INTERMEDIATE THEREOF AND USE THEREOF | 苏州长禾药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| CN-112939948-A | Novel quinazoline-containing compound, intermediate and application thereof | 苏州长禾药业股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20150366868-A1 | CANCER TREATMENT METHOD | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-8444988-B2 | Cancer treatment method | GLAXOSMITHKLINE LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120058113-A1 | CANCER TREATMENT METHOD | NOVARTIS AG (CH) | 2012-03-08 | — | — | US | disclosed |
| US-20110312982-A1 | Cancer Treatment Method | NOVARTIS AG (CH) | 2011-12-22 | — | — | US | disclosed |
| US-20100249160-A1 | Cancer Treatment Method | LEO OSPREY LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| US-20070148261-A1 | CANCER TREATMENT METHOD | LEO OSPREY LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| US-7141576-B2 | 4-quinazolineamine derivatives; antineoplastic agents; inhibitors of erb family tyrosine kinases and/or epidermal growth factor receptors | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2006-11-28 | — | — | US | disclosed |
| EP-1353693-B1 | PHARMACEUTICAL COMBINATION CONTAINING A 4-QUINAZOLINEAMINE AND PACLITAXEL, CARBOPLATIN OR VINORELBINE FOR THE TREATMENT OF CANCER | GLAXO GROUP LTD (GB) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512413-A2 | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer | GLAXO GROUP LIMITED (GB) | 2005-03-09 | — | — | EP | disclosed |
| EP-1488809-A1 | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-20040053946-A1 | Cancer treatment method | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058113-A1 | CANCER TREATMENT METHOD | TP53, HNMT, TOP2B | EGFR 361/4885APP 4879/4885FLT1 2715/4885 |
| US-20110312982-A1 | Cancer Treatment Method | HNMT, TP53, TUBB4A | EGFR 354/4885APP 4878/4885FLT1 2834/4885 |
| US-20150366868-A1 | CANCER TREATMENT METHOD | TP53, HNMT, TOP2B | EGFR 361/4885APP 4879/4885FLT1 2715/4885 |
| US-20040053946-A1 | Cancer treatment method | TP53, HNMT, TOP2B | EGFR 361/4885APP 4879/4885FLT1 2715/4885 |
| US-20070148261-A1 | CANCER TREATMENT METHOD | TP53, HNMT, TOP2B | EGFR 361/4885APP 4879/4885FLT1 2715/4885 |
| US-20100249160-A1 | Cancer Treatment Method | TP53, HNMT, TOP2B | EGFR 361/4885APP 4879/4885FLT1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.